Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ENC1018 in Healthy Adults
NCT06224400Phase 1Completed
- Sponsor
- EnnovaBio
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENC1018 in ulcerative colitis (UC) (4 arms), sponsored by EnnovaBio. Primary endpoints: Treatment Emergent Adverse Events, Severity of Treatment Emergent Adverse Events and 4 more. Started Mar 2024; status: completed.
02
Drugs
ENC1018
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06224400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224400.